Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
Sales | 9,526,155 | 8,574,726 | 7,933,230 | 7,690,185 | 6,652,436 |
Cost of Goods | 1,448,192 | 1,418,098 | 1,147,762 | 1,179,026 | 1,143,126 |
Gross Profit | 8,077,962 | 7,156,628 | 6,785,468 | 6,511,159 | 5,509,311 |
Operating Expenses | 4,207,256 | 3,227,428 | 3,296,193 | 2,907,676 | 3,164,658 |
Operating Income | 3,870,901 | 3,929,298 | 3,490,037 | 3,603,509 | 2,344,778 |
Interest Expense | -260,988 | 316,528 | -94,527 | 161,680 | -338,261 |
Other Income | -138,534 | 484,428 | -41,054 | 122,773 | -447,459 |
Pre-tax Income | 3,993,355 | 4,097,198 | 3,543,510 | 3,564,602 | 2,235,580 |
Income Tax | 818,001 | 815,410 | 705,079 | 709,404 | 369,578 |
Net Income Continuous | 3,175,355 | 3,281,788 | 2,838,431 | 2,855,198 | 1,866,001 |
Net Income | $3,175,355 | $3,281,788 | $2,838,431 | $2,855,198 | $1,866,001 |
EPS Basic Total Ops | 0.71 | 0.73 | 0.63 | 0.64 | 0.41 |
EPS Basic Continuous Ops | 0.71 | 0.73 | 0.63 | 0.63 | 0.41 |
EPS Diluted Total Ops | 0.71 | 0.73 | 0.63 | 0.63 | 0.41 |
EPS Diluted Continuous Ops | 0.71 | 0.73 | 0.63 | 0.63 | 0.51 |
EPS Diluted Before Non-Recurring Items | 0.71 | 0.73 | 0.63 | 0.64 | 0.42 |
EBITDA(a) | $4,300,201 | $4,297,558 | $3,811,534 | $3,851,217 | $2,666,494 |